The Drug That Does Everything
A 600,000-person study shows GLP-1 drugs reduce addiction risk across alcohol, opioids, and tobacco — while the Wegovy pill hits 400,000 subscribers and the FDA cracks down on compounders.
Nora Whitfield
Bureau: Chicago
Weight Loss by Subscription: Novo Nordisk's Wegovy Pill Hits 400,000 Subscribers in Three Months
Novo Nordisk hit 400,000 Wegovy subscribers in three months, turning weight-loss medication into a Netflix-style recurring revenue play.
FDA Cracks Down on Telehealth GLP-1 Compounders in Access vs. Safety Battle
The FDA has sent warning letters to 30 telehealth companies selling compounded GLP-1 weight-loss drugs, escalating a battle between pharmaceutical access advocates and safety regulators.
The Helium Shortage Is Now Affecting Hospital MRI Machines
Qatar's helium exports died with the Hormuz blockade — now hospitals worldwide face MRI scan delays because the magnets need liquid helium to function.
The Ozempic Menu: America's Restaurants Are Shrinking to Match America's Appetite
Olive Garden, Chipotle, and Subway have all introduced smaller-portion menus as GLP-1 drugs reshape how tens of millions of Americans eat out.